Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications

Beshara Sheehan; Christina Guo; Antje Neeb; Alec Paschalis; Shahneen Sandhu; Johann S. de Bono

doi:10.1016/j.euf.2021.06.006

Back

Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications

Article 2021 en

Abstract

1 min read

Prostate-specific membrane antigen (PSMA) is a promising, novel theranostic target in advanced prostate cancer (PCa). Multiple PSMA-targeted therapies are currently in clinical development, with some agents showing impressive antitumour activity, although optimal patient selection and therapeutic resistance remain ongoing challenges.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2021

Radionuclide Therapy in Prostate Cancer: From Standalone to Combination PSMA Theranostics

Shahneen Sandhu, Christina Guo, Michael S. Hofman

Article2017

Prostate-specific membrane antigen theranostics

Justin Ferdinandus, John Violet, Shahneen Sandhu, Michael S. Hofman

Article2020

Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting

Andrea K. Miyahira, Kenneth J. Pienta, John W. Babich, Neil H. Bander, Jérémie Calais, Peter L. Choyke, Michael S. Hofman, Steven M. Larson, Frank I. Lin, Michael J. Morris, Martin G. Pomper, Shahneen Sandhu, Howard I. Scher, Scott T. Tagawa, Scott Williams, Howard R. Soule

Article2023

Novel radionuclide therapy combinations in prostate cancer

Andrisha–Jade Inderjeeth, Amir Iravani, Shalini Subramaniam, Ciara Conduit, Shahneen Sandhu

Article2003

Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients

Thomas D Schmittgen, Sabine Teske, Robert L. Vessella, Lawrence D. True, Brian A. Zakrajsek